Chronic Inflammation by Age: Your 40s, 50s and 60s

Inflammaging is the slow, persistent rise in chronic inflammation that accumulates with age, distinct from the acute inflammation that heals a wound or fights an infection, and far more damaging over time. Where acute inflammation is short-lived and purposeful, inflammaging is a continuous, low-grade immune activation that quietly damages tissues, consumes energy, and accelerates biological aging. It is now recognized as one of the 12 hallmarks of aging, and it does not stand alone. It is mechanistically linked to mitochondrial dysfunction, disabled autophagy, cardiovascular disease, insulin resistance, type 2 diabetes, and neurodegeneration.

For women moving through their 40s, 50s, and 60s, inflammaging does not follow a straight line. Estrogen, a potent anti-inflammatory agent, shapes the entire trajectory, and its decline during perimenopause triggers a shift in the immune system that accelerates biological aging in ways that standard blood panels rarely capture. Understanding how chronic inflammation shifts at each life stage is the first step toward measuring it accurately and acting on it before disease appears.

For a deeper look at how glycan biomarkers measure this process, see our guide Chronic Inflammation & Inflammaging: The Hidden Driver of How You Age.

What actually causes chronic inflammation to increase as we age?

Chronic inflammation rises with age through two primary biological mechanisms: mitochondrial dysfunction, which increases reactive oxygen species and oxidative stress, and a decline in autophagy, the cellular process that clears dead cells and debris, which allows inflammatory signals to accumulate unchecked. These processes create a self-reinforcing cycle: low-grade inflammation causes microscopic tissue damage, that damage is repaired imperfectly, and the repair process itself generates more inflammation.

Beyond these internal mechanisms, external drivers compound the effect. Smoking, physical inactivity, poor diet, high adiposity, disturbed sleep, social isolation, and psychological stress all independently drive systemic chronic inflammatiom. Visceral and ectopic fat are particularly significant: adipose tissue secretes pro-inflammatory cytokines including interleukin-6 and TNF-alpha, and as fat cells expand, those deeper in the tissue become hypoxic, triggering further inflammatory signaling. Microbiome dysbiosis, increasingly common with age and processed-food diets, adds another layer.

The result is that by midlife, most people are carrying a chronic inflammatory burden shaped by decades of accumulated biology, behavior, and environment. The challenge is that this burden is largely asymptomatic and difficult to detect with standard tools.

"From a functional medicine perspective, we look at the root causes that drive inflammation. What causes your immune system to become unbalanced and unhealthy? The factors in your environment — how you sleep, how you eat, how you move, how you control stress and respond to stress. Then there are your biological predeterminants: how healthy is your gut lining, how toxic is your environment, and how are you able to process those toxins through detoxification pathways. Inflammation is a constant check-in process. If we allow our body to deplete, we allow inflammation to accumulate."

— Dr. E, Functional Medicine Physician, HUM2N

How does inflammation change specifically in your 40s, during perimenopause?

In the 40s, the most significant driver of accelerating inflammation for women is the hormonal transition of perimenopause, and the change is measurable at the molecular level. Estrogen functions as an anti-inflammatory agent throughout the reproductive years: it downregulates adhesion and chemokine molecules, attenuates immune cell recruitment, and keeps pro-inflammatory cytokine concentrations low. As estrogen begins to decline in perimenopause, this protective effect erodes rapidly.

GlycanAge data consistently shows this pattern across the perimenopausal transition. Evidence from multiple cohorts and clinical observations indicates that women can biologically age by more than a decade in glycan years within only a few months. In women who were functioning significantly below their chronological age before perimenopause, the absolute jump can be larger, with Prof. Gordan Lauc noting observed cases of deterioration by 10 to 20 glycan years during this transition.

"We see in women in this perimenopause period that glycans very quickly change from immunosuppressive glycans — glycans which suppress inflammation — into glycans which actually promote inflammation. We believe this is not only a biomarker; this is actually a molecule which is causing damage because it's promoting inflammation."

— Prof. Gordan Lauc, CSO and Co-Founder of GlycanAge

Why do women age differently from men when it comes to inflammation?

Men's inflammatory glycan profiles change in a roughly linear fashion across the lifespan — a steady, gradual increase in pro-inflammatory markers as they age. Women follow a fundamentally different pattern. In their reproductive years, women's inflammation levels are actually lower than men's of the same age, reflecting estrogen's anti-inflammatory protection. Then, as perimenopause arrives, there is a sharp, non-linear acceleration, a sigmoidal curve, that brings women's inflammatory profile to the same level as men's, and sometimes beyond it.

This difference is not incidental. It has direct implications for mortality risk. Women who go through menopause before the age of 40 have a 25% higher risk of all-cause mortality compared to women who go through menopause between ages 45 and 49. The earlier the estrogen loss, the earlier the inflammatory acceleration, and the earlier the downstream disease risk compounds.

The clinical implication is that a woman's biological age cannot be assessed using the same assumptions applied to men. The hormonal context is inseparable from the inflammatory biology, and any measurement of biological age that does not account for this distinction will systematically misread where a woman actually is in her aging trajectory.

What happens to inflammation in your 50s, after menopause?

After menopause, the acute hormonal transition stabilizes, but the inflammatory shift it triggered does not reverse on its own. The pro-inflammatory glycan profile established during perimenopause persists into postmenopause, and the immune system enters a state of chronic imbalance, not simply overactive, but dysregulated. Elements of the immune system that were previously modulated by estrogen become over-stimulated, generating ongoing chronic inflammation that affects multiple organ systems simultaneously.

The downstream consequences are well-documented. Postmenopausal women face a significantly increased risk of cardiovascular disease, metabolic disease, changes in fat distribution, and age-related inflammatory conditions. Cognitive decline and heightened susceptibility to autoimmune conditions are also associated with this postmenopausal inflammatory state. Pre-existing inflammatory conditions frequently worsen after menopause, because the estrogen that was partially suppressing them is no longer present.

This is the decade in which inflammaging shifts from a background process to a clinically significant one, and the decade in which measuring it accurately, rather than inferring it from symptoms, becomes most actionable.

Is chronic inflammation in your 60s inevitable, or can it be influenced?

Chronic inflammation increases with age as a biological reality, but its rate and severity are substantially shaped by modifiable factors, and the evidence from glycan research confirms that meaningful change is achievable at any age. Biological age, as measured through IgG glycosylation, is 40% heritable and 60% determined by lifestyle, diet, exercise, stress, fitness level, and hormones. That 60% is the territory where intervention works.

The mechanisms are clear. Unhealthy behaviors, such as poor diet, physical inactivity, smoking, disturbed sleep, high adiposity, independently drive systemic chronic inflammation, and addressing them produces measurable glycan changes. Estrogen replacement, where clinically appropriate, has been shown in a randomized, double-blind, placebo-controlled trial to prevent the pro-inflammatory glycan shift that follows estrogen suppression: women who received estrogen replacement maintained stable glycan profiles, while those on placebo showed a sharp increase in pro-inflammatory markers. When the intervention was withdrawn and normal menstrual cycles resumed, glycan profiles returned to baseline, confirming that the inflammatory shift is hormonally driven and, to a significant degree, hormonally reversible.

For anyone in their 60s, the key question is not whether inflammation can be influenced, but whether the interventions already in place are measurably working. That requires measurement, not assumption.

How is chronic inflammation measured accurately across these life stages?

Most existing biomarkers capture acute inflammation, which is the rapid, short-term immune response to injury or infection, rather than the chronic, low-grade inflammation that drives biological aging. Standard blood panels, including CRP and white cell counts, fluctuate on an hourly and daily basis and are largely blind to the persistent inflammatory signal that accumulates over years. This is why chronic inflammation is one of the hardest processes to detect with standard clinical tools

GlycanAge measures chronic inflammation directly through IgG glycosylation, the pattern of glycans (complex sugars) attached to immunoglobulin G antibodies in the blood. These glycans are not passive markers; they are functional effectors that actively determine whether an antibody promotes or suppresses inflammation. By analyzing the glycan structures on IgG antibodies from a simple finger-prick blood sample, GlycanAge calculates the ratio of pro-inflammatory to anti-inflammatory glycans and expresses this as a biological age, producing a direct readout of how the immune system is aging, distinct from chronological age.

Critically, glycan-based biological age is responsive to interventions in 3–6 months and stable in the absence of biological change, making it suitable for tracking whether a specific lifestyle change, hormone therapy, or clinical intervention is actually working. This combination of responsiveness and stability is what distinguishes GlycanAge from epigenetic clocks, which can vary by up to 10 years between repeat measurements in the same individual without any intervention, making it difficult to distinguish real biological change from measurement noise.

"IgG glycosylation determines the effector functions of immunoglobulins. Changing a single monosaccharide in a glycan can completely convert the function of an immunoglobulin from pro-inflammatory to anti-inflammatory. We know that immunoglobulins in people change as we age, and that the functional properties of our immune system also change, because the glycosylation of IgG changes."

— Prof. Gordan Lauc, Co-Founder & Chief Scientific Officer, GlycanAge

Can hormone replacement therapy (HRT) actually lower biological age as measured by glycans?

HRT has a direct, measurable effect on the glycan-based inflammatory profile, and the evidence comes from a randomized, double-blind, placebo-controlled trial, not observational data. In that study, a group of women had their hormones suppressed with gonadotropin-releasing hormone therapy, artificially inducing a postmenopausal state. Half received estrogen replacement; half received a placebo. Women in the estrogen group maintained stable glycan profiles and their biological age remained essentially unchanged. Women in the placebo group showed a sharp, rapid increase in pro-inflammatory glycans.

When the intervention ended and normal hormonal function resumed, glycan profiles in both groups returned to baseline. This confirms two things: estrogen directly modulates the inflammatory glycan profile, and the pro-inflammatory shift of menopause is not a permanent, irreversible change,but a hormonally driven state that responds to hormonal intervention.

For women evaluating HRT, this means GlycanAge can serve as an objective measure of whether hormone therapy is working at the biological level, not just whether symptoms have improved, but whether the underlying inflammatory trajectory has changed. In clinical practice, women on well-managed HRT protocols have shown biological age reductions ranging from 8 to 25 years, based on documented cases from GlycanAge's clinical partner network. In some cases, biological age improvements were not detectable through symptom tracking alone, but were clearly visible in glycan data.

What should I actually do with this information — how do I start measuring my inflammatory age?

The first step is establishing a baseline. Without a measurement, there is no way to know where your inflammatory biology currently sits, how far your biological age diverges from your chronological age, or whether any intervention you are already doing is having an effect. For women in their 40s, 50s, and 60s, particularly those navigating perimenopause, menopause, or postmenopause, that baseline is the foundation for every subsequent decision about lifestyle, hormones, and clinical care. Clinicians managing perimenopausal patients will find GlycanAge equally useful as an objective measure to guide treatment decisions and track the biological impact of interventions over time.

GlycanAge provides that baseline through an at-home finger-prick test that analyzes IgG glycosylation from a small blood sample. Results arrive within 2–3 weeks via a personal dashboard, and every test includes a 1:1 Result Interpretation Call with a longevity specialist who walks through biological age, glycan indexes, disease-association patterns, and a personalized health plan. From there, retesting every 6–12 months, or 3–6 months after a specific intervention, gives you a longitudinal picture of whether your biology is moving in the right direction.

The question to bring to your clinician is not just "what are my inflammation markers?" but "what is my biological age, and is it changing?" Those are different questions, and only one of them has an answer that responds to what you actually do.

If you are ready to measure where your inflammatory biology stands right now, order a GlycanAge test kit and book your Result Interpretation Call.

Order Your GlycanAge Test Kit

External Sources

• https://pubmed.ncbi.nlm.nih.gov/36599349/ — López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243–278.

• https://pubmed.ncbi.nlm.nih.gov/23382691/ — Lauc G, Huffman JE, Pučić M, et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet. 2013;9(1):e1003225.

• https://pubmed.ncbi.nlm.nih.gov/17167474/ — Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867.